{"metadata":{"kernelspec":{"language":"python","display_name":"Python 3","name":"python3"},"language_info":{"name":"python","version":"3.11.13","mimetype":"text/x-python","codemirror_mode":{"name":"ipython","version":3},"pygments_lexer":"ipython3","nbconvert_exporter":"python","file_extension":".py"},"kaggle":{"accelerator":"none","dataSources":[],"dockerImageVersionId":31192,"isInternetEnabled":true,"language":"python","sourceType":"notebook","isGpuEnabled":false}},"nbformat_minor":4,"nbformat":4,"cells":[{"cell_type":"code","source":"import os\nfrom kaggle_secrets import UserSecretsClient\n\ntry:\n    GOOGLE_API_KEY = UserSecretsClient().get_secret(\"GOOGLE_API_KEY\")\n    os.environ[\"GOOGLE_API_KEY\"] = GOOGLE_API_KEY\n    print(\"‚úÖ Gemini API key setup complete.\")\nexcept Exception as e:\n    print(\n        f\"üîë Authentication Error: Please make sure you have added 'GOOGLE_API_KEY' to your Kaggle secrets. Details: {e}\"\n    )","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T03:40:45.098601Z","iopub.execute_input":"2025-11-17T03:40:45.099096Z","iopub.status.idle":"2025-11-17T03:40:45.312228Z","shell.execute_reply.started":"2025-11-17T03:40:45.099055Z","shell.execute_reply":"2025-11-17T03:40:45.311084Z"}},"outputs":[{"name":"stdout","text":"‚úÖ Gemini API key setup complete.\n","output_type":"stream"}],"execution_count":3},{"cell_type":"code","source":"from typing import Any, Dict\n\nfrom google.adk.agents import Agent, LlmAgent\nfrom google.adk.apps.app import App, EventsCompactionConfig\nfrom google.adk.models.google_llm import Gemini\nfrom google.adk.sessions import DatabaseSessionService\nfrom google.adk.sessions import InMemorySessionService\nfrom google.adk.runners import Runner\nfrom google.adk.tools.tool_context import ToolContext\nfrom google.genai import types\n\nprint(\"‚úÖ ADK components imported successfully.\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T03:41:52.299904Z","iopub.execute_input":"2025-11-17T03:41:52.300281Z","iopub.status.idle":"2025-11-17T03:42:01.812168Z","shell.execute_reply.started":"2025-11-17T03:41:52.300256Z","shell.execute_reply":"2025-11-17T03:42:01.811218Z"}},"outputs":[{"name":"stdout","text":"‚úÖ ADK components imported successfully.\n","output_type":"stream"}],"execution_count":5},{"cell_type":"code","source":"session_service = InMemorySessionService()\nUSER_ID = \"prakriti\"\nMODEL_NAME = \"gemini-2.0-flash-exp\"\n\nprint(\"‚úÖ Session service and variables created!\")\n","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T03:44:05.195936Z","iopub.execute_input":"2025-11-17T03:44:05.196331Z","iopub.status.idle":"2025-11-17T03:44:05.202364Z","shell.execute_reply.started":"2025-11-17T03:44:05.196307Z","shell.execute_reply":"2025-11-17T03:44:05.201094Z"}},"outputs":[{"name":"stdout","text":"‚úÖ Session service and variables created!\n","output_type":"stream"}],"execution_count":6},{"cell_type":"code","source":"# Define helper functions that will be reused throughout the notebook\nasync def run_session(\n    runner_instance: Runner,\n    user_queries: list[str] | str = None,\n    session_name: str = \"default\",\n):\n    print(f\"\\n ### Session: {session_name}\")\n\n    # Get app name from the Runner\n    app_name = runner_instance.app_name\n\n    # Attempt to create a new session or retrieve an existing one\n    try:\n        session = await session_service.create_session(\n            app_name=app_name, user_id=USER_ID, session_id=session_name\n        )\n    except:\n        session = await session_service.get_session(\n            app_name=app_name, user_id=USER_ID, session_id=session_name\n        )\n    # Process queries if provided\n    if user_queries:\n        # Convert single query to list for uniform processing\n        if type(user_queries) == str:\n            user_queries = [user_queries]\n\n        # Process each query in the list sequentially\n        for query in user_queries:\n            print(f\"\\nUser > {query}\")\n\n            # Convert the query string to the ADK Content format\n            query = types.Content(role=\"user\", parts=[types.Part(text=query)])\n\n            # Stream the agent's response asynchronously\n            async for event in runner_instance.run_async(\n                user_id=USER_ID, session_id=session.id, new_message=query\n            ):\n                # Check if the event contains valid content\n                if event.content and event.content.parts:\n                    # Filter out empty or \"None\" responses before printing\n                    if (\n                        event.content.parts[0].text != \"None\"\n                        and event.content.parts[0].text\n                    ):\n                        print(f\"{MODEL_NAME} > \", event.content.parts[0].text)\n    else:\n        print(\"No queries!\")\n\n\n\nprint(\"‚úÖ Helper functions defined.\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T03:44:50.551735Z","iopub.execute_input":"2025-11-17T03:44:50.552790Z","iopub.status.idle":"2025-11-17T03:44:50.560738Z","shell.execute_reply.started":"2025-11-17T03:44:50.552739Z","shell.execute_reply":"2025-11-17T03:44:50.559843Z"}},"outputs":[{"name":"stdout","text":"‚úÖ Helper functions defined.\n","output_type":"stream"}],"execution_count":9},{"cell_type":"code","source":"retry_config = types.HttpRetryOptions(\n    attempts=5,  # Maximum retry attempts\n    exp_base=7,  # Delay multiplier\n    initial_delay=1,\n    http_status_codes=[429, 500, 503, 504],  # Retry on these HTTP errors\n)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T03:45:00.120279Z","iopub.execute_input":"2025-11-17T03:45:00.120597Z","iopub.status.idle":"2025-11-17T03:45:00.126511Z","shell.execute_reply.started":"2025-11-17T03:45:00.120574Z","shell.execute_reply":"2025-11-17T03:45:00.125375Z"}},"outputs":[],"execution_count":10},{"cell_type":"code","source":"APP_NAME = \"default\"  # Application\nUSER_ID = \"default\"  # User\nSESSION = \"default\"  # Session\n\nMODEL_NAME = \"gemini-2.5-flash-lite\"\n\n\n# Step 1: Create the LLM Agent\nroot_agent = Agent(\n    model=Gemini(model=\"gemini-2.5-flash-lite\", retry_options=retry_config),\n    name=\"text_chat_bot\",\n    description=\"A text chatbot\",  # Description of the agent's purpose\n)\n# Step 2: Set up Session Management\n# InMemorySessionService stores conversations in RAM (temporary)\nsession_service = InMemorySessionService()\n\n# Step 3: Create the Runner\nrunner = Runner(agent=root_agent, app_name=APP_NAME, session_service=session_service)\n\nprint(\"‚úÖ Stateful agent initialized!\")\nprint(f\"   - Application: {APP_NAME}\")\nprint(f\"   - User: {USER_ID}\")\nprint(f\"   - Using: {session_service.__class__.__name__}\")\n","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T03:57:59.435555Z","iopub.execute_input":"2025-11-17T03:57:59.436354Z","iopub.status.idle":"2025-11-17T03:57:59.443539Z","shell.execute_reply.started":"2025-11-17T03:57:59.436320Z","shell.execute_reply":"2025-11-17T03:57:59.442596Z"}},"outputs":[{"name":"stdout","text":"‚úÖ Stateful agent initialized!\n   - Application: default\n   - User: default\n   - Using: InMemorySessionService\n","output_type":"stream"}],"execution_count":11},{"cell_type":"code","source":"await run_session(\n    runner,\n    [\n        \"Hi, I am Sam! What is the capital of United States?\",\n        \"Hello! What is my name?\",  # This time, the agent should remember!\n    ],\n    \"stateful-agentic-session\",\n)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T03:58:35.421659Z","iopub.execute_input":"2025-11-17T03:58:35.422554Z","iopub.status.idle":"2025-11-17T03:58:36.614203Z","shell.execute_reply.started":"2025-11-17T03:58:35.422518Z","shell.execute_reply":"2025-11-17T03:58:36.613306Z"}},"outputs":[{"name":"stdout","text":"\n ### Session: stateful-agentic-session\n\nUser > Hi, I am Sam! What is the capital of United States?\ngemini-2.5-flash-lite >  Hi Sam! The capital of the United States is Washington, D.C.\n\nUser > Hello! What is my name?\ngemini-2.5-flash-lite >  Your name is Sam!\n","output_type":"stream"}],"execution_count":12},{"cell_type":"code","source":"await run_session(\n    runner,\n    [\n        \"Hi, Prakriti is missing Dipesh. What is the capital city of Nepal?\",\n        \" Hi, Who is the Prime minister of Nepal\"\n    ],\n    \"stateful-agentic-session\",\n)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T04:06:54.496206Z","iopub.execute_input":"2025-11-17T04:06:54.496728Z","iopub.status.idle":"2025-11-17T04:06:55.114427Z","shell.execute_reply.started":"2025-11-17T04:06:54.496697Z","shell.execute_reply":"2025-11-17T04:06:55.113176Z"}},"outputs":[{"name":"stdout","text":"\n ### Session: stateful-agentic-session\n\nUser > Hi, Prakriti is missing Dipesh. What is the capital city of Nepal?\ngemini-2.5-flash-lite >  The capital city of Nepal is Kathmandu.\n\nUser >  Hi, Who is the Prime minister of Nepal\ngemini-2.5-flash-lite >  The Prime Minister of Nepal is Pushpa Kamal Dahal.\n","output_type":"stream"}],"execution_count":18},{"cell_type":"code","source":"await run_session(\n    runner,\n    \"By the way, what's my name and which country was I asking about?\",\n    \"stateful-agentic-session\",  # ‚Üê SAME SESSION!\n)\n","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T04:07:28.578116Z","iopub.execute_input":"2025-11-17T04:07:28.578458Z","iopub.status.idle":"2025-11-17T04:07:29.160192Z","shell.execute_reply.started":"2025-11-17T04:07:28.578434Z","shell.execute_reply":"2025-11-17T04:07:29.159225Z"}},"outputs":[{"name":"stdout","text":"\n ### Session: stateful-agentic-session\n\nUser > By the way, what's my name and which country was I asking about?\ngemini-2.5-flash-lite >  You are Sam, and you were asking about Nepal.\n","output_type":"stream"}],"execution_count":19},{"cell_type":"code","source":"await run_session(\n    runner,\n    [\"What did I ask you about earlier?\", \"And remind me, what's my name?\"],\n    \"stateful-agentic-session\",\n)  # Note, we are using same session name","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T05:02:24.506613Z","iopub.execute_input":"2025-11-17T05:02:24.507592Z","iopub.status.idle":"2025-11-17T05:02:25.448759Z","shell.execute_reply.started":"2025-11-17T05:02:24.507557Z","shell.execute_reply":"2025-11-17T05:02:25.447601Z"}},"outputs":[{"name":"stdout","text":"\n ### Session: stateful-agentic-session\n\nUser > What did I ask you about earlier?\ngemini-2.5-flash-lite >  You asked me about:\n\n*   The capital of the United States.\n*   Your name.\n*   That Prakriti is missing Dipesh.\n*   The capital city of Nepal.\n*   The Prime Minister of Nepal.\n\nUser > And remind me, what's my name?\ngemini-2.5-flash-lite >  Your name is Sam.\n","output_type":"stream"}],"execution_count":20},{"cell_type":"code","source":"# Step 1: Create the same agent (notice we use LlmAgent this time)\nchatbot_agent = LlmAgent(\n    model=Gemini(model=\"gemini-2.5-flash-lite\", retry_options=retry_config),\n    name=\"text_chat_bot\",\n    description=\"A text chatbot with persistent memory\",\n)\n\n# Step 2: Switch to DatabaseSessionService\n# SQLite database will be created automatically\ndb_url = \"sqlite:///my_agent_data.db\"  # Local SQLite file\nsession_service = DatabaseSessionService(db_url=db_url)\n\n# Step 3: Create a new runner with persistent storage\nrunner = Runner(agent=chatbot_agent, app_name=APP_NAME, session_service=session_service)\n\nprint(\"‚úÖ Upgraded to persistent sessions!\")\nprint(f\"   - Database: my_agent_data.db\")\nprint(f\"   - Sessions will survive restarts!\")\n","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T05:02:47.465210Z","iopub.execute_input":"2025-11-17T05:02:47.465538Z","iopub.status.idle":"2025-11-17T05:02:47.669634Z","shell.execute_reply.started":"2025-11-17T05:02:47.465515Z","shell.execute_reply":"2025-11-17T05:02:47.668728Z"}},"outputs":[{"name":"stdout","text":"‚úÖ Upgraded to persistent sessions!\n   - Database: my_agent_data.db\n   - Sessions will survive restarts!\n","output_type":"stream"}],"execution_count":21},{"cell_type":"code","source":"await run_session(\n    runner,\n    [\"Hi, I am Sam! What is the capital of the United States?\", \"Hello! What is my name?\"],\n    \"test-db-session-01\",\n)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T05:02:53.113503Z","iopub.execute_input":"2025-11-17T05:02:53.113790Z","iopub.status.idle":"2025-11-17T05:02:54.213486Z","shell.execute_reply.started":"2025-11-17T05:02:53.113771Z","shell.execute_reply":"2025-11-17T05:02:54.212364Z"}},"outputs":[{"name":"stdout","text":"\n ### Session: test-db-session-01\n\nUser > Hi, I am Sam! What is the capital of the United States?\ngemini-2.5-flash-lite >  Hi Sam! The capital of the United States is Washington, D.C.\n\nUser > Hello! What is my name?\ngemini-2.5-flash-lite >  Your name is Sam.\n","output_type":"stream"}],"execution_count":22},{"cell_type":"code","source":"await run_session(\n    runner,\n    [\"What is the capital of India?\", \"Hello! What is my name?\"],\n    \"test-db-session-01\",\n)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T05:02:58.356999Z","iopub.execute_input":"2025-11-17T05:02:58.357489Z","iopub.status.idle":"2025-11-17T05:02:59.366007Z","shell.execute_reply.started":"2025-11-17T05:02:58.357457Z","shell.execute_reply":"2025-11-17T05:02:59.364810Z"}},"outputs":[{"name":"stdout","text":"\n ### Session: test-db-session-01\n\nUser > What is the capital of India?\ngemini-2.5-flash-lite >  The capital of India is New Delhi.\n\nUser > Hello! What is my name?\ngemini-2.5-flash-lite >  Your name is Sam.\n","output_type":"stream"}],"execution_count":23},{"cell_type":"code","source":"await run_session(\n    runner, [\"Hello! What is my name?\"], \"test-db-session-02\"\n)  # Note, we are using new session name","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T05:03:03.077303Z","iopub.execute_input":"2025-11-17T05:03:03.077653Z","iopub.status.idle":"2025-11-17T05:03:03.471675Z","shell.execute_reply.started":"2025-11-17T05:03:03.077630Z","shell.execute_reply":"2025-11-17T05:03:03.470384Z"}},"outputs":[{"name":"stdout","text":"\n ### Session: test-db-session-02\n\nUser > Hello! What is my name?\ngemini-2.5-flash-lite >  I do not have access to your personal information, including your name. I am a text-based chatbot and do not store any user data.\n","output_type":"stream"}],"execution_count":24},{"cell_type":"code","source":"import sqlite3\n\ndef check_data_in_db():\n    with sqlite3.connect(\"my_agent_data.db\") as connection:\n        cursor = connection.cursor()\n        result = cursor.execute(\n            \"select app_name, session_id, author, content from events\"\n        )\n        print([_[0] for _ in result.description])\n        for each in result.fetchall():\n            print(each)\n\n\ncheck_data_in_db()","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T05:03:14.059090Z","iopub.execute_input":"2025-11-17T05:03:14.059454Z","iopub.status.idle":"2025-11-17T05:03:14.067544Z","shell.execute_reply.started":"2025-11-17T05:03:14.059430Z","shell.execute_reply":"2025-11-17T05:03:14.066504Z"}},"outputs":[{"name":"stdout","text":"['app_name', 'session_id', 'author', 'content']\n('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"Hi, I am Sam! What is the capital of the United States?\"}], \"role\": \"user\"}')\n('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"Hi Sam! The capital of the United States is Washington, D.C.\"}], \"role\": \"model\"}')\n('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"Hello! What is my name?\"}], \"role\": \"user\"}')\n('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"Your name is Sam.\"}], \"role\": \"model\"}')\n('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"What is the capital of India?\"}], \"role\": \"user\"}')\n('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"The capital of India is New Delhi.\"}], \"role\": \"model\"}')\n('default', 'test-db-session-01', 'user', '{\"parts\": [{\"text\": \"Hello! What is my name?\"}], \"role\": \"user\"}')\n('default', 'test-db-session-01', 'text_chat_bot', '{\"parts\": [{\"text\": \"Your name is Sam.\"}], \"role\": \"model\"}')\n('default', 'test-db-session-02', 'user', '{\"parts\": [{\"text\": \"Hello! What is my name?\"}], \"role\": \"user\"}')\n('default', 'test-db-session-02', 'text_chat_bot', '{\"parts\": [{\"text\": \"I do not have access to your personal information, including your name. I am a text-based chatbot and do not store any user data.\"}], \"role\": \"model\"}')\n","output_type":"stream"}],"execution_count":25},{"cell_type":"code","source":"# Re-define our app with Events Compaction enabled\nresearch_app_compacting = App(\n    name=\"research_app_compacting\",\n    root_agent=chatbot_agent,\n    # This is the new part!\n    events_compaction_config=EventsCompactionConfig(\n        compaction_interval=3,  # Trigger compaction every 3 invocations\n        overlap_size=1,  # Keep 1 previous turn for context\n    ),\n)\n\ndb_url = \"sqlite:///my_agent_data.db\"  # Local SQLite file\nsession_service = DatabaseSessionService(db_url=db_url)\n\n# Create a new runner for our upgraded app\nresearch_runner_compacting = Runner(\n    app=research_app_compacting, session_service=session_service\n)\n\n\nprint(\"‚úÖ Research App upgraded with Events Compaction!\")\n","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T05:03:23.414304Z","iopub.execute_input":"2025-11-17T05:03:23.414676Z","iopub.status.idle":"2025-11-17T05:03:23.426553Z","shell.execute_reply.started":"2025-11-17T05:03:23.414647Z","shell.execute_reply":"2025-11-17T05:03:23.425422Z"}},"outputs":[{"name":"stdout","text":"‚úÖ Research App upgraded with Events Compaction!\n","output_type":"stream"},{"name":"stderr","text":"/tmp/ipykernel_48/1130018423.py:6: UserWarning: [EXPERIMENTAL] EventsCompactionConfig: This feature is experimental and may change or be removed in future versions without notice. It may introduce breaking changes at any time.\n  events_compaction_config=EventsCompactionConfig(\n","output_type":"stream"}],"execution_count":26},{"cell_type":"code","source":"# Turn 1\nawait run_session(\n    research_runner_compacting,\n    \"What is the latest news about AI in healthcare?\",\n    \"compaction_demo\",\n)\n\n# Turn 2\nawait run_session(\n    research_runner_compacting,\n    \"Are there any new developments in drug discovery?\",\n    \"compaction_demo\",\n)\n\n# Turn 3 - Compaction should trigger after this turn!\nawait run_session(\n    research_runner_compacting,\n    \"Tell me more about the second development you found.\",\n    \"compaction_demo\",\n)\n\n# Turn 4\nawait run_session(\n    research_runner_compacting,\n    \"Who are the main companies involved in that?\",\n    \"compaction_demo\",\n)\n","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T05:03:33.595880Z","iopub.execute_input":"2025-11-17T05:03:33.596281Z","iopub.status.idle":"2025-11-17T05:03:48.171182Z","shell.execute_reply.started":"2025-11-17T05:03:33.596255Z","shell.execute_reply":"2025-11-17T05:03:48.170173Z"}},"outputs":[{"name":"stdout","text":"\n ### Session: compaction_demo\n\nUser > What is the latest news about AI in healthcare?\ngemini-2.5-flash-lite >  The field of AI in healthcare is incredibly dynamic, with new developments happening almost daily! Here's a summary of some of the latest trends and significant news, categorized for clarity:\n\n**1. Diagnostics and Imaging:**\n\n*   **Advancements in AI for Medical Imaging:** This remains a huge area. AI algorithms are getting better and better at detecting subtle anomalies in X-rays, CT scans, MRIs, and pathology slides that human eyes might miss. Recent news often highlights AI's improved accuracy and speed in identifying conditions like:\n    *   **Cancer:** Detecting early-stage lung cancer nodules, breast cancer mammograms, and skin cancer from images.\n    *   **Diabetic Retinopathy:** Identifying early signs of damage to the retina from diabetes.\n    *   **Stroke Detection:** Rapidly analyzing brain scans to identify the type and location of a stroke, guiding treatment decisions.\n*   **AI-Powered Pathology:** AI is transforming pathology by analyzing tissue samples, aiding in diagnosis, grading tumors, and predicting treatment response.\n*   **Personalized Diagnostic Approaches:** AI is being used to analyze a combination of imaging, genomic, and clinical data to provide more personalized diagnostic insights.\n\n**2. Drug Discovery and Development:**\n\n*   **Accelerating Drug Discovery:** AI is significantly speeding up the process of identifying potential drug candidates and predicting their efficacy and safety. Companies are using AI to:\n    *   Analyze vast datasets of molecular structures and biological interactions.\n    *   Design novel molecules with desired properties.\n    *   Predict how drugs will behave in the human body.\n*   **Repurposing Existing Drugs:** AI can identify existing drugs that might be effective for new diseases, saving considerable time and cost in development.\n*   **Clinical Trial Optimization:** AI is being used to identify suitable patient populations for clinical trials, predict trial outcomes, and monitor patient progress more effectively.\n\n**3. Personalized Medicine and Treatment:**\n\n*   **Tailoring Treatments to Individuals:** AI is crucial for analyzing a patient's unique genetic makeup, lifestyle, and medical history to recommend the most effective and personalized treatment plans. This is particularly impactful in:\n    *   **Oncology:** Predicting which cancer treatments will be most effective for a specific patient based on their tumor's genetic profile.\n    *   **Chronic Disease Management:** Developing personalized plans for conditions like diabetes, heart disease, and autoimmune disorders.\n*   **Predictive Analytics for Patient Outcomes:** AI models are being developed to predict a patient's risk of developing certain conditions or experiencing adverse events, allowing for proactive interventions.\n\n**4. Workflow Optimization and Administrative Tasks:**\n\n*   **Reducing Administrative Burden:** AI is being deployed to automate routine administrative tasks, such as:\n    *   **Medical Coding and Billing:** Improving accuracy and efficiency.\n    *   **Scheduling Appointments:** Optimizing clinic flow.\n    *   **Transcribing Medical Notes:** Freeing up clinicians' time.\n*   **Improving Hospital Operations:** AI can help manage hospital resources, predict patient flow, and optimize staffing.\n\n**5. AI in Patient Care and Monitoring:**\n\n*   **Remote Patient Monitoring:** Wearable devices and AI algorithms are enabling continuous monitoring of patients outside of traditional healthcare settings, detecting early signs of deterioration and alerting caregivers.\n*   **Virtual Assistants and Chatbots:** AI-powered chatbots are being used for patient education, answering FAQs, triaging symptoms, and providing mental health support.\n*   **Surgical Robotics and Assistance:** AI is enhancing robotic surgery by providing real-time guidance to surgeons, improving precision, and enabling less invasive procedures.\n\n**Key Trends and Considerations:**\n\n*   **Regulatory Scrutiny:** As AI in healthcare becomes more prevalent, regulatory bodies like the FDA are increasing their focus on ensuring the safety, efficacy, and ethical use of these technologies.\n*   **Data Privacy and Security:** Protecting sensitive patient data is paramount. Advances in AI are often accompanied by discussions and developments in data anonymization, federated learning, and robust cybersecurity measures.\n*   **AI Explainability (XAI):** There's a growing demand for AI models that can explain their decision-making processes, especially in critical healthcare applications, to build trust and facilitate clinical adoption.\n*   **Interoperability:** Ensuring that AI systems can seamlessly integrate with existing Electronic Health Records (EHRs) and other healthcare IT infrastructure remains a challenge and an ongoing area of development.\n*   **Ethical Considerations:** Discussions around bias in AI algorithms, equitable access to AI-powered healthcare, and the potential impact on the physician-patient relationship are ongoing.\n\n**Where to find the latest news:**\n\n*   **Reputable Healthcare Technology News Sites:** Websites like Fierce Healthcare, STAT News, Healthcare IT News, MobiHealthNews, and HIMSS are excellent sources.\n*   **Medical Journals:** Publications like JAMA, The Lancet, Nature Medicine, and NEJM often feature research on AI in healthcare.\n*   **Tech News Outlets:** Major tech news sites like TechCrunch, The Verge, and Wired also cover significant AI advancements in various sectors, including healthcare.\n*   **Industry Conferences and Reports:** Stay updated on major healthcare AI conferences and reports from leading research firms.\n\nTo get the *absolute latest* news, I'd recommend checking these sources regularly, as the field moves incredibly fast!\n\n ### Session: compaction_demo\n\nUser > Are there any new developments in drug discovery?\ngemini-2.5-flash-lite >  Yes, there are **constant and exciting new developments** in drug discovery powered by AI! This is one of the most impactful areas where AI is revolutionizing healthcare. Here's a breakdown of some of the latest trends and specific examples:\n\n**Key Areas of Advancement:**\n\n1.  **Accelerated Target Identification:**\n    *   **AI analyzing vast 'omics' data:** AI algorithms are becoming incredibly adept at sifting through massive datasets of genomics, proteomics, transcriptomics, and metabolomics to identify novel biological targets (proteins, genes, pathways) that play a crucial role in diseases. This was traditionally a laborious and time-consuming process.\n    *   **Predicting disease drivers:** AI can help pinpoint the root causes of complex diseases by understanding intricate biological networks, leading to more precise targeting.\n\n2.  **Novel Molecule Design and Optimization:**\n    *   **Generative AI for De Novo Design:** This is a major breakthrough. Generative models (like GANs and VAEs) can now design entirely new molecules from scratch, optimizing them for specific properties such as binding affinity to a target, solubility, and reduced toxicity. This goes beyond just screening existing libraries.\n    *   **Predicting Drug Properties:** AI models are becoming more accurate at predicting a molecule's ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties early in the discovery process, reducing the number of \"failures\" in later stages.\n    *   **Fragment-Based Drug Design Enhancement:** AI can suggest novel ways to combine molecular fragments to create potent drug candidates.\n\n3.  **Drug Repurposing:**\n    *   **Identifying New Uses for Old Drugs:** AI can analyze known drug-target interactions, disease pathways, and scientific literature to identify existing approved drugs that might be effective for new indications. This significantly shortens development timelines and reduces costs.\n    *   **Examples:** AI has been instrumental in identifying potential treatments for rare diseases and even for emerging infectious diseases (like COVID-19, where some existing drugs were investigated for new uses).\n\n4.  **Clinical Trial Optimization:**\n    *   **Predicting Trial Success:** AI can analyze historical trial data and patient characteristics to predict the likelihood of success for new drug candidates in clinical trials.\n    *   **Patient Stratification:** AI helps identify specific patient subgroups who are most likely to respond to a particular drug, leading to more efficient and ethical clinical trials.\n    *   **Biomarker Discovery:** AI can help discover novel biomarkers that indicate disease progression or treatment response, which are crucial for monitoring patients in trials.\n\n**Examples of Companies and Platforms Driving Innovation:**\n\n*   **Recursion Pharmaceuticals:** Uses AI and automation to analyze vast biological datasets and discover new drug targets and therapies.\n*   **Exscientia:** Focuses on AI-driven drug design and has achieved significant milestones in bringing AI-designed drugs into clinical trials.\n*   **Atomwise:** Employs deep learning for structure-based drug discovery, predicting how small molecules will bind to target proteins.\n*   **BenevolentAI:** Uses AI to mine scientific literature and data to discover new drug targets and potential treatments.\n*   **Insilico Medicine:** Known for its end-to-end AI platform for drug discovery, from target identification to clinical trials. They recently announced the first fully AI-discovered and AI-designed drug candidate entering human trials.\n\n**Recent Notable News and Trends:**\n\n*   **AI-Designed Drug Entering Human Trials:** A significant milestone reported recently is the advancement of a drug candidate designed and discovered entirely by AI into Phase 1 clinical trials. This is a strong validation of AI's capabilities in this domain.\n*   **Focus on Protein Degraders:** AI is being used to design novel proteolysis-targeting chimeras (PROTACs) and molecular glues, which are emerging classes of therapeutics that work by degrading disease-causing proteins rather than just inhibiting them.\n*   **Large Language Models (LLMs) for Drug Discovery:** LLMs are starting to be applied to tasks like summarizing research papers, generating hypotheses, and even assisting in writing scientific reports, further streamlining the discovery process.\n*   **AI for Small Molecule and Biologics Discovery:** While AI has been strong in small molecule discovery, it's increasingly being applied to the design and optimization of biologics like antibodies and peptides.\n\n**Challenges and Future Outlook:**\n\nDespite the rapid progress, challenges remain, including:\n\n*   **Data Quality and Standardization:** Ensuring access to high-quality, standardized biological data is crucial for training effective AI models.\n*   **Experimental Validation:** AI predictions still require rigorous experimental validation, which remains a bottleneck.\n*   **Regulatory Pathways:** Clearer regulatory frameworks for AI-discovered drugs are still evolving.\n*   **Explainability:** Understanding *why* an AI model makes a certain prediction can be complex but is vital for trust and further refinement.\n\nHowever, the overall trajectory is overwhelmingly positive. AI is no longer just a theoretical concept in drug discovery; it's a powerful, operational tool that is accelerating the pace of innovation and holding immense promise for developing novel therapies for a wide range of diseases.\n\n ### Session: compaction_demo\n\nUser > Tell me more about the second development you found.\ngemini-2.5-flash-lite >  You're likely referring to the **\"Novel Molecule Design and Optimization\"** development I mentioned, which is indeed a very exciting and cutting-edge area of AI in drug discovery.\n\nLet me elaborate on what this entails and why it's such a significant advancement:\n\n**The Core Idea: Creating Drugs That Don't Exist Yet**\n\nTraditionally, drug discovery involved:\n\n1.  **Screening existing libraries:** Testing thousands or millions of known chemical compounds to see if any show activity against a disease target.\n2.  **Modifying known drugs:** Taking a drug that shows some promise and making small chemical tweaks to improve its properties.\n\n\"Novel Molecule Design and Optimization\" using AI takes a fundamentally different approach: **creating entirely new drug candidates from scratch, tailored to a specific need.**\n\n**How AI Enables This:**\n\nThis is primarily driven by **Generative AI** and sophisticated **machine learning models**. Here's how it works:\n\n1.  **Understanding the Target:** AI models are trained on vast amounts of data about proteins, enzymes, and other biological targets involved in diseases. This includes their 3D structures, how they interact with other molecules, and the chemical properties that allow binding.\n\n2.  **Generative Models for De Novo Design:**\n    *   **What are Generative Models?** Think of them as AI systems that can *create* new data that resembles the data they were trained on. In this context, they are trained on millions of existing molecules and their properties.\n    *   **How they work:** These models can learn the \"rules\" of chemistry and molecular structure. They can then be prompted to generate *new* molecular structures that haven't been synthesized before.\n    *   **Examples of Generative Models:**\n        *   **Generative Adversarial Networks (GANs):** These involve two neural networks competing. One network (the generator) creates new molecules, and the other (the discriminator) tries to tell if they are \"real\" (from the training data) or \"fake\" (generated). This competitive process drives the generator to produce increasingly realistic and useful molecules.\n        *   **Variational Autoencoders (VAEs):** These models learn a compressed representation (a \"latent space\") of molecular structures and then can decode this representation to generate new, diverse molecules.\n        *   **Reinforcement Learning (RL):** RL can be used in conjunction with generative models. The AI \"agent\" proposes molecules, and a \"reward function\" (based on desired properties like binding affinity or drug-likeness) guides the agent to generate better and better molecules over time.\n\n3.  **Optimization Based on Desired Properties:**\n    *   **Beyond Just Binding:** Simply binding to a target isn't enough. A drug needs to be soluble, stable, able to enter cells, not toxic, and easily metabolized or excreted.\n    *   **Predictive Models:** AI models are trained to predict these crucial **ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity)** properties of a generated molecule *in silico* (on a computer).\n    *   **Iterative Refinement:** The generative process is often iterative. The AI generates a molecule, its properties are predicted, and then the generative model is fine-tuned to create molecules that are even better across multiple desired characteristics. This is like a sculptor constantly refining their work.\n\n**Why is This a Breakthrough?**\n\n*   **Speed:** It drastically shortens the time it takes to identify promising drug candidates compared to traditional methods. Instead of months or years of screening, AI can generate novel candidates in days or weeks.\n*   **Novelty:** AI can explore chemical spaces that human chemists might not have considered, potentially leading to entirely new classes of drugs with unique mechanisms of action.\n*   **Precision:** By optimizing for multiple properties simultaneously, AI can design molecules that are not only effective but also safer and more likely to succeed in clinical trials.\n*   **Tackling \"Undruggable\" Targets:** For diseases where the biological targets are difficult to interact with using traditional small molecules, AI can help design entirely new molecular architectures that can effectively bind and modulate these targets.\n\n**In essence, AI-driven novel molecule design is like having an incredibly skilled and tireless chemist who can explore an unimaginably vast library of potential drug structures, optimizing them for effectiveness and safety simultaneously.** This capability is what's driving many of the recent breakthroughs and high-profile investments in AI-powered drug discovery companies.\n\n ### Session: compaction_demo\n\nUser > Who are the main companies involved in that?\ngemini-2.5-flash-lite >  The landscape of companies leveraging AI for novel molecule design and optimization is rapidly expanding and includes a mix of established pharmaceutical giants experimenting with AI, and a vibrant ecosystem of **AI-native biotech companies** that have built their entire platforms around this technology.\n\nHere are some of the main players and categories of companies involved:\n\n**1. Dedicated AI-Native Drug Discovery Companies (Often Leading the Charge):**\n\nThese companies have AI at the very core of their operations, from target identification to molecule design and even early clinical trial planning.\n\n*   **Insilico Medicine:** One of the most prominent examples. They have an end-to-end AI platform and recently achieved a significant milestone with an AI-discovered and AI-designed drug entering human trials. They focus on various therapeutic areas, including oncology and fibrosis.\n*   **Exscientia:** A pioneer in AI-driven drug design. They have a strong track record of partnering with large pharma companies and have multiple AI-designed drug candidates in clinical development across different disease areas.\n*   **Recursion Pharmaceuticals:** While also strong in target identification and experimental automation, Recursion uses AI to analyze biological images and identify potential therapeutic interventions, including novel molecule design.\n*   **Absci:** Focuses on AI for designing and discovering biologics (like antibodies) using their proprietary AI drug discovery platform.\n*   **Relay Therapeutics:** Leverages AI and cryogenic electron microscopy to understand protein motion and design drugs that precisely target these dynamic processes.\n*   **Schr√∂dinger:** While a long-standing player in computational chemistry, Schr√∂dinger has significantly integrated AI into its platform for molecular design, prediction, and optimization, enabling the discovery of novel molecules.\n*   **Generate Biomedicines:** Aims to use AI to \"program\" proteins and antibodies, essentially designing novel biologics from scratch.\n\n**2. Large Pharmaceutical Companies with Internal AI Efforts and Partnerships:**\n\nMajor pharmaceutical companies are heavily investing in building their own AI capabilities and partnering with AI-native biotechs.\n\n*   **Pfizer:** Actively uses AI across its R&D pipeline, including drug design and discovery. They have collaborations with companies like Insilico Medicine.\n*   **Novartis:** Has a dedicated AI innovation lab and has been incorporating AI into its drug discovery processes for several years.\n*   **Merck (MSD):** Investing in AI for various R&D functions, including identifying novel targets and designing molecules.\n*   **AstraZeneca:** Has made significant investments in AI and data science for drug discovery, including partnerships and internal development.\n*   **Roche/Genentech:** A leader in leveraging data and AI for drug discovery and development, particularly in oncology.\n*   **Sanofi:** Actively pursuing AI-driven drug discovery, often through strategic partnerships.\n*   **Bristol Myers Squibb:** Incorporating AI and machine learning across its research and development, with a focus on predictive modeling and design.\n\n**3. Technology Providers and Platform Companies:**\n\nThese companies provide the underlying AI technologies, software, and cloud infrastructure that enable drug discovery.\n\n*   **NVIDIA:** Their GPUs and AI software platforms (like Clara Discovery) are crucial for the computational power needed for complex molecular simulations and AI model training.\n*   **Google Cloud / Amazon Web Services (AWS) / Microsoft Azure:** Provide the cloud computing infrastructure and AI/ML services that many biotech companies rely on.\n*   **Various AI/ML software providers:** Companies offering specialized tools for cheminformatics, bioinformatics, and machine learning model development.\n\n**Key Trends Driving Involvement:**\n\n*   **\"AI-First\" Biotech:** The emergence of startups that are founded with AI as their primary driver for innovation.\n*   **Strategic Partnerships:** Large pharma companies recognizing the need to access cutting-edge AI expertise through collaborations and acquisitions.\n*   **Democratization of AI Tools:** The increasing availability of powerful AI platforms and cloud computing makes advanced AI capabilities more accessible to a wider range of researchers.\n\nIt's important to note that this field is incredibly dynamic. New companies are emerging, and existing ones are constantly evolving their platforms and strategies. The companies listed above represent some of the most prominent and influential in the AI-driven novel molecule design space as of now.\n","output_type":"stream"}],"execution_count":27},{"cell_type":"code","source":"# Get the final session state\nfinal_session = await session_service.get_session(\n    app_name=research_runner_compacting.app_name,\n    user_id=USER_ID,\n    session_id=\"compaction_demo\",\n)\n\nprint(\"--- Searching for Compaction Summary Event ---\")\nfound_summary = False\nfor event in final_session.events:\n    # Compaction events have a 'compaction' attribute\n    if event.actions and event.actions.compaction:\n        print(\"\\n‚úÖ SUCCESS! Found the Compaction Event:\")\n        print(f\"  Author: {event.author}\")\n        print(f\"\\n Compacted information: {event}\")\n        found_summary = True\n        break\n\nif not found_summary:\n    print(\n        \"\\n‚ùå No compaction event found. Try increasing the number of turns in the demo.\"\n    )","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-11-17T05:03:56.871229Z","iopub.execute_input":"2025-11-17T05:03:56.871623Z","iopub.status.idle":"2025-11-17T05:03:56.887595Z","shell.execute_reply.started":"2025-11-17T05:03:56.871597Z","shell.execute_reply":"2025-11-17T05:03:56.886319Z"}},"outputs":[{"name":"stdout","text":"--- Searching for Compaction Summary Event ---\n\n‚úÖ SUCCESS! Found the Compaction Event:\n  Author: user\n\n Compacted information: model_version=None content=None grounding_metadata=None partial=None turn_complete=None finish_reason=None error_code=None error_message=None interrupted=None custom_metadata=None usage_metadata=None live_session_resumption_update=None input_transcription=None output_transcription=None avg_logprobs=None logprobs_result=None cache_metadata=None citation_metadata=None invocation_id='03604d6f-c514-41a7-8289-fb2c4574bb05' author='user' actions=EventActions(skip_summarization=None, state_delta={}, artifact_delta={}, transfer_to_agent=None, escalate=None, requested_auth_configs={}, requested_tool_confirmations={}, compaction={'start_timestamp': 1763355813.636223, 'end_timestamp': 1763355821.125001, 'compacted_content': {'parts': [{'function_call': None, 'code_execution_result': None, 'executable_code': None, 'file_data': None, 'function_response': None, 'inline_data': None, 'text': 'The user initially inquired about the latest news in AI in healthcare. The AI agent provided a comprehensive overview covering diagnostics and imaging, drug discovery and development, personalized medicine, workflow optimization, and patient care. Key trends like regulatory scrutiny, data privacy, AI explainability, interoperability, and ethical considerations were also highlighted.\\n\\nFollowing this, the user specifically asked about new developments in drug discovery. The AI agent detailed advancements in target identification, novel molecule design and optimization, drug repurposing, and clinical trial optimization. It also provided examples of companies and platforms leading innovation in this space, mentioning recent milestones like AI-designed drugs entering human trials.\\n\\nThe user then asked for more information on the \"second development\" mentioned, which the AI identified as \"Novel Molecule Design and Optimization.\" The AI agent elaborated on this by explaining how AI, particularly generative AI (GANs, VAEs, RL), creates entirely new molecules from scratch, unlike traditional screening methods. It detailed how AI models understand targets, generate novel structures, and optimize them for desired properties like ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). The AI emphasized the breakthrough nature of this approach due to its speed, novelty, precision, and ability to tackle challenging targets.\\n\\n**Key Information and Decisions:**\\n\\n*   **User\\'s primary interest:** Latest news in AI in healthcare, then specifically AI in drug discovery.\\n*   **AI\\'s initial response:** Broad overview of AI in healthcare, categorizing advancements.\\n*   **AI\\'s detailed response on drug discovery:** Focused on four key areas, including \"Novel Molecule Design and Optimization.\"\\n*   **User\\'s request for clarification:** Prompted a deeper dive into the molecule design aspect.\\n*   **AI\\'s explanation of novel molecule design:** Provided a detailed explanation of the process, technologies involved (generative AI), and its significance.\\n\\n**Unresolved Questions or Tasks:**\\n\\n*   None. The conversation has been a series of informative exchanges where the AI has provided detailed responses to the user\\'s questions. The user has not yet indicated further questions or tasks.', 'thought': None, 'thought_signature': None, 'video_metadata': None}], 'role': 'model'}}, end_of_agent=None, agent_state=None, rewind_before_invocation_id=None) long_running_tool_ids=set() branch=None id='1f9fa714-e8f4-47af-850e-715fde7a0edf' timestamp=1763355826.484587\n","output_type":"stream"}],"execution_count":28}]}